Global Needle-free Drug Delivery Products Market $21.2 Billion by 2029

The global market for needle-free drug delivery products market predicted to attain $21.2 billion by 2029, expanding at a CAGR of 9.1% over the forecast period, driven by growing demand for treatments using higher dosage formulations, especially in the delivery of biologics.

• In the recent years, the needle-free injection technologies (NFITs), including injection systems designed to deliver drugs subcutaneously without using a needle to pierce the skin have gained popularity worldwide.
  • The needle-free injection systems have been able to reduce needle anxiety, injection-related pain, needlestick injuries and infection and/or disease transmission.

In the past several decades, tremendous progress has been made toward the development of safe, effective, and convenient means of drug administration. The new generation of needle-free drug delivery systems decrease the risks of needle stick injuries to healthcare personnel and to prevent improper reuse of syringes and needles.

• The needle-free technology offers the very obvious benefit of effective drug delivery for a wide range of drugs and bio-equivalent to syringe and needle, resulting in less pain, and is strongly preferred by patients.
  • Additional benefits include very fast injection compared with conventional needles and no needle disposal issues. Not only it can benefit the pharmaceutical industry in increasing product sales, it has the added potential to increase compliance with dosage regimens and improved outcomes.
    • Similarly, a portal device jet-injects a rapid, high-pressure stream of medicine, as thin as a strand of hair, through the skin in adjustable doses. A smart app tracks each dose, monitoring the effects and uploads the data to the Cloud for patients and doctors to review.
• Various brands of jet injectors available in global market include Biojector 2000 (Bioject Medical Technologies), SUMAVEL DosePro (Zogenix), E-Jet 100 (Eurojet Medical), Stratis (Pharmajet), ZetaJet (Bioject Medical Technologies), LectraJet (D’Antonio Consultants International), Med-Jet (Medical International Technologies), Vision (Antares Pharma), Glide SDI (Glide Pharmaceutical Technologies), AdvantaJet (Activa Brand Products), J-Tip (National Medical Products), SQ-Pen (Diabetes Management International), Vitajet (Bioject Medical Technologies) and Penjet (Penjet Corporation).

For example, transdermal drug delivery involves placing a drug on the skin in the form of a patch, cream, or lotion wherein the drug permeates across the skin and enters the bloodstream. 

• Key advantages of transdermal delivery include the easy accessibility of skin, which encourages patient compliance, avoidance of the gastrointestinal tract, and sustained release over extended periods of time. 
  • Two classes of transdermal patches are currently available:
    • Reservoir-type patches
    • Matrix-type patches
  • A number of drugs, including scopolamine, nitroglycerin, nicotine, clonidine, fentanyl, estradiol, testosterone, lidocaine, and oxybutinin, are routinely delivered transdermally by skin patches.
• Some of the leading brands for transdermal patches available in the market are Estraderm (CIBA) for estradiol, Duragesic (Janssen) for fentanyl, Testoderm (ALZA) for testosterone and Minitran (3M) for nitroglycerin.

The global needle free drug delivery devices market report provides market size ($Million 2019 to 2029), market share, growth trends and forecast (CAGR%, 2022 to 2029). 

The global needle-free drug delivery devices market segmented by technology [jet injectors, competing needle-free technology (novel needle technology, inhaler technology, transdermal patch technology)], its applications (diabetes, pediatrics, pain management, vaccination, others), and geography.

• Based on the technologies, the competing needle-free technologies segment registered the largest revenue share of the global market, whereas the novel needle technologies segment dominated the overall technology market.
  • The insulin delivery devices for diabetes segment led the applications segment, registering the fastest double-digit growth rate during the forecast period, followed by the pain management drug delivery products segment.
• However, the pediatric injection devices segment expected to grow at the fastest CAGR throughout the next five years period.

The global market for needle-free drug delivery products research report is further divided by geography (regional and country based) into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

• In terms of geography, the North America needle-free drug delivery devices market accounted for the largest market share globally, owing to high public awareness, wider adoption, and introduction of novel needle-free products in community vaccination programs.
  • On the other hand, the Asia Pacific region anticipated to be the most attractive market, driven by rising incidences of asthma, COPD, diabetes, osteoarthritis, infectious diseases in the emerging economies.

The global needle-free drug delivery devices market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major competitors operating in the global market for needle-free drug delivery products and included in this report are Antares Pharma, Inc., Glide Pharmaceutical Technologies Ltd., Injex Pharma AG, 3M Company, Pharmajet, Inc., and Zogenix, Inc.

• Technology
  • Jet Injectors
  • Competing Needle-free Technology
    • Novel Needle Technology
    • Inhaler Technology
    • Transdermal Patch Technology
• Application
  • Diabetes
  • Pediatrics
  • Pain Management
  • Vaccination
  • Others
• Geography
  • North America (U.S., Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
  • Asia Pacific (Japan, China, India, Rest of APAC)
  • Latin America (Brazil, Mexico, Rest of LA)
  • Rest of the World
• Company Profiles
  • 3M Company
  • Antares Pharma, Inc.
  • Glide Pharmaceutical Technologies Ltd.
  • Injex Pharma AG
  • Pharmajet, Inc.
  • Zogenix, Inc.

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/needle-free-drug-delivery-devices-market/

Related publications:

• Needle Free Drug Delivery Devices Market by Technology [Jet Injectors, Competing Needle-free Technology (Novel Needle Technology, Inhaler Technology, Transdermal Patch Technology)], by Application (Diabetes, Pediatrics, Pain Management, Vaccination, Others) and Forecast 2022-2029
• Global Injectable Drug Delivery Products Market $10.1 Billion by 2027
• Global Drug Delivery Systems Market $31.5 Billion by 2027
• Global Dermatology Products Market $29.6 Billion by 2029
• Safety Syringes Market by Product [Retractable Safety Syringes (Automatic Retractable Safety Syringes, Manual Retractable Safety Syringes), Non-Retractable Safety Syringes (Sheathing Tube Safety Syringes, Hinged Needle Cover Syringes, Sliding Needle Cover Syringes), Application (Drug delivery, Vaccination, Blood Collection , Anesthesia, Others), End User (Hospitals, Ambulatory Surgical Centers, Physician Clinics, Home Care, Others) and Forecast 2022-2029